MDxHealth (NASDAQ:MDXH) Stock Keeps “Neutral” Rating at BTIG Research

BTIG Research reiterated their neutral rating on shares of MDxHealth (NASDAQ:MDXH) in a report released on Monday morning, Marketbeat reports.

MDXH has been the topic of a number of other research reports. Weiss Ratings downgraded shares of MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Wall Street Zen raised shares of MDxHealth to a “sell” rating in a research note on Saturday, August 15th. Lake Street Capital cut shares of MDxHealth from a “buy” rating to a “hold” rating and set a $0.50 price objective for the company. in a research note on Friday. Finally, Craig Hallum downgraded MDxHealth from a “buy” rating to a “hold” rating in a report on Friday. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $1.33.

MDxHealth Price Performance

Shares of MDXH stock opened at $0.18 on Monday. The firm’s 50-day simple moving average is $0.64 and its 200-day simple moving average is $0.90. MDxHealth has a 1-year low of $0.17 and a 1-year high of $5.33. The firm has a market cap of $9.07 million, a P/E ratio of -0.25 and a beta of 1.68.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. The company had revenue of $27.21 million during the quarter, compared to analyst estimates of $26.14 million. Analysts expect that MDxHealth will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MDXH. Squarepoint Ops LLC purchased a new stake in shares of MDxHealth in the second quarter worth about $82,000. Bank of America Corp DE grew its stake in shares of MDxHealth by 213.9% in the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after buying an additional 29,638 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after buying an additional 54,600 shares in the last quarter. Finally, Perkins Capital Management Inc. grew its stake in shares of MDxHealth by 7.1% in the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after buying an additional 97,500 shares in the last quarter.

About MDxHealth

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.